Insurers' ill-fated $48 billion tie-up hits dead end, but battle
over damages looms
By Anna Wilde Mathews and Brent Kendall
Anthem Inc. said it would finally give up on its ill-starred
deal for Cigna Corp., setting the stage for a rancorous court
battle between the companies over billions in potential
damages.
The fight will play out in a Delaware court where each company
has sued the other, both alleging breaches of their merger
agreement. Late Thursday, a Delaware judge denied Anthem's request
to keep Cigna locked in the $48 billion deal as Anthem continued
trying to overcome antitrust rulings against the combination -- but
he also signaled that Anthem appeared to have a good chance of
proving its case that Cigna had violated their pact.
Anthem and Cigna originally unveiled their deal in July 2015,
amid a frenzy of health-insurer deal-making that aimed to
consolidate the top of the industry into a few behemoths that could
wield enormous negotiating heft. But behind-the-scenes conflict
between the two partners quickly set in, even as they publicly
moved forward with their combination. Last year, the Justice
Department filed an antitrust suit to block the deal, which would
have created a company with a huge footprint in commercial
insurance. A federal judge ruled against the merger in February and
an appeals court upheld that decision last month. Anthem had sought
to appeal that verdict to the Supreme Court.
But Anthem said Friday that it was giving Cigna notice that it
was terminating the merger agreement. Anthem immediately reiterated
its argument that its erstwhile partner sabotaged the deal, and it
said Cigna isn't entitled to the $1.85 billion breakup fee laid out
in the merger agreement. The bigger insurer said it would seek to
claim "massive damages" against Cigna.
Cigna, for its part, wants the $1.85 billion and an additional
$13 billion in damages from Anthem. In a statement Friday, Cigna
said it believed Anthem didn't use its "reasonable best efforts" to
get regulatory approval, and as a result the acquisition was
blocked. Cigna said it seeks the damages against Anthem "for the
harm that it caused Cigna and its shareholders." It also said it
would ramp up its share repurchases in the wake of the deal's
formal termination.
Jeffrey S. Jacobovitz, an antitrust lawyer with Arnall Golden
Gregory LLP, said it isn't uncommon for there to be hard feelings
between merging companies when a deal goes sour, "but you never
really see bad blood like you've seen here." The situation "was
highly unusual, particularly for two companies that wanted to get
married, at least at the start," Mr. Jacobovitz said. The
hostilities appeared even deeper than in a normal hostile-takeover
transaction, he added.
The Delaware judge who will oversee the dueling Anthem and Cigna
suits, Vice Chancellor J. Travis Laster, of the Delaware Chancery
Court, said in his Thursday decision that Anthem "has a reasonable
probability of prevailing on its claim" that Cigna breached the
deal terms. The record in the antitrust proceedings indicates that
"Cigna did not oppose the antitrust lawsuit fully or vigorously, as
it was required to do," he said. However, he said it was a "tossup"
whether Anthem would be able to prove that Cigna's actions led to
the deal's failure to win antitrust approvals.
The judge also wrote that if Anthem's account of Cigna's
behavior is correct, "then the damages it can recover from Cigna
are potentially massive. ... At this point, in my view, a damages
award is the only realistic form of relief."
A long and bitter legal road lies ahead, as the two sides spar
over who did what to whom and rehash the troubled history of their
deal.
The fight is already intensely personal, with Anthem accusing
Cigna's chief executive, David Cordani, along with others at the
company, of working against the deal after Mr. Cordani was at one
point offered a postmerger position that fell short of the scope he
thought was due to him. "Furious that he was not being provided
with all of the postmerger powers that he desired, Cordani walked
out of the meeting and never again would meet with [Anthem CEO
Joseph R.] Swedish one-on-one," Anthem said in a filing.
Anthem said that Mr. Cordani was later offered broader
responsibilities but "Cordanni, nonetheless, disengaged from the
merger process and Cigna embarked on an unprecedented campaign to
sabotage the merger and procure a $1.85 billion termination fee."
Anthem said Cigna hired lawyers specifically to focus on ensuring
it could get the termination fee, and it undermined Anthem's
arguments for the deal in the antitrust case.
For its part, Cigna argues that the merger failed to pass
antitrust muster because of the strategy that Anthem chose in
defending the deal, which Cigna says was selected over its
objections. Cigna said in a filing that Mr. Swedish and another
Anthem executive plotted to "'get rid of Cordani' even before the
merger agreement was negotiated and were still discussing their
desire to 'take him out' months after the deal was signed." At
another point, Cigna said, Mr. Swedish called Mr. Cordani "a
'bully' and refused to meet with him."
Cigna said that it "undertook enormous efforts toward
integration."
Even when merger partners have tensions in the wake of a failed
deal, litigation is unusual, said Jonathan Corsico, an attorney at
Gibson, Dunn & Crutcher. Usually, executives say, "'it's over,
let's move on,'" he said. Also, many contingencies for a blocked
deal are pre-negotiated in the merger agreement, heading off
suits.
It is also rare for merging companies to work at cross-purposes
during a government antitrust review and court case. For instance,
the Anthem-Cigna situation stands in contrast to court proceedings
in 2015, when the Justice Department challenged Electrolux AB's
planned $3.3 billion purchase of General Electric Co.'s appliance
business. GE participated in the merger defense with Electrolux,
even as it was considering exercising its right to terminate the
deal.
GE, facing an improved market for its business, ultimately
walked away from the merger during the court case, and later sold
its appliance business to Chinese manufacturer Haier Group for $5.4
billion.
There has been recent litigation involving other quarrelsome
merger partners, although under different circumstances.
Abbott Laboratories, for example, last year agreed to acquire
Alere Inc. but the deal produced tensions, with both sides going to
court. Alere filed a lawsuit to force Abbott to complete the
transaction, while Abbott filed suit seeking to get out of it,
saying that developments had reduced Alere's value. The two sides
reached a pact last month, with Abbott agreeing to pay a lower
price for Alere.
--Anne Steele contributed to this article.
Write to Anna Wilde Mathews at anna.mathews@wsj.com and Brent
Kendall at brent.kendall@wsj.com
(END) Dow Jones Newswires
May 13, 2017 02:47 ET (06:47 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Cigna (NYSE:CI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cigna (NYSE:CI)
Historical Stock Chart
From Apr 2023 to Apr 2024